HealthDay News — Work-time activity behavior, rather than leisure-time or non-workday, seems to be associated with 24-hour ambulatory blood pressure, according to a study published online in Medicine ...

HealthDay News — Trajectories of emotion regulation across ages 3 to 7 years predict attention-deficit/hyperactivity disorder (ADHD) symptoms, as well as conduct problems, according to a study ...

The American Academy of Sleep Medicine published guidance regarding the treatment of restless leg syndrome and periodic limb movement disorder.

After peak in 2020, significant decrease seen in firearm injury-related visit rates year over year from 2020 to 2023 ...

Researchers assessed the safety and efficacy of apremilast over a 48-week period for the treatment of early oligoarticular psoriatic arthritis.

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks.

The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...

No new safety concerns were observed through 16 weeks among pediatric patients with juvenile psoriatic arthritis or enthesitis-related arthritis receiving ixekizumab. Ixekizumab (IXE) demonstrated ...

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates ...

Respondents who participated in continuing medical education had the highest familiarity with TD therapies. Managing patients with tardive dyskinesia (TD) requires evolving educational needs, with ...